Trevena Appoints Barry Shin as Chief Financial Officer
June 27 2019 - 7:00AM
Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused
on the development and commercialization of novel medicines for
patients with Central Nervous System (CNS) conditions, today
announced the appointment of Barry Shin as Chief Financial Officer.
Mr. Shin comes to the Company with over 17 years of investment
banking and corporate advisory experience, focused in the
biopharmaceuticals sector.
“We are thrilled to have Barry join the Trevena team at this
exciting point in our progress,” said Carrie Bourdow. “We
have several significant near-term milestones on the horizon,
including receipt of top-line data from our ongoing healthy
volunteer QT study for oliceridine in the fourth quarter of this
year, followed by NDA resubmission. Barry’s strategic and
financial experience will be invaluable as we advance oliceridine
and our innovative portfolio of CNS assets.”
“I’m delighted to join Trevena’s outstanding leadership team,”
said Barry Shin. “I look forward to being part of the
company’s growth as it brings important new therapeutic options,
starting with oliceridine, to patients in need.”
Mr. Shin joins Trevena with extensive experience advising
biopharmaceutical companies through merger and acquisition
(M&A) and financing transactions. He was previously
Managing Director in the Healthcare Investment Banking Group at
Mizuho Securities. Prior to joining Mizuho Securities, he was
a Managing Director in Guggenheim Securities’ Healthcare Investment
Banking Group from 2012 to 2017. From 2005 to 2012, he served
in positions of increasing responsibility within the Healthcare
Investment Banking Group of Piper Jaffray. From 2001 to 2005,
he advised healthcare and technology companies in financing and
M&A transactions as a corporate attorney. Mr. Shin
received a B.Sc. and joint J.D. / M.B.A. from the University of
Toronto.
About TrevenaTrevena, Inc. is a
biopharmaceutical company focused on the development and
commercialization of novel medicines for patients with Central
Nervous System conditions. The Company has four novel and
differentiated investigational drug candidates, including IV
oliceridine, for the management of moderate to severe acute pain in
hospitals, TRV250 for the acute treatment of migraine, and TRV734
for maintenance treatment of opioid use disorder. The Company has
also identified TRV045, a novel S1P receptor modulator that may
offer a new, non-opioid approach to managing chronic pain.
Forward-Looking StatementsAny statements in
this press release about future expectations, plans and prospects
for the Company, including statements about the Company’s strategy,
future operations, clinical development of its therapeutic
candidates, plans for potential future product candidates and other
statements containing the words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,”
“project,” “suggest,” “target,” “potential,” “will,” “would,”
“could,” “should,” “continue,” and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including: the status,
timing, costs, results and interpretation of the Company’s clinical
trials; the uncertainties inherent in conducting clinical trials;
expectations for regulatory approvals, including for oliceridine;
availability of funding sufficient for the Company’s foreseeable
and unforeseeable operating expenses and capital expenditure
requirements; uncertainties related to the Company’s intellectual
property; other matters that could affect the availability or
commercial potential of the Company’s therapeutic candidates; and
other factors discussed in the Risk Factors set forth in the
Company’s Annual Report on Form 10-K and Quarterly Reports on Form
10-Q filed with the Securities and Exchange Commission (SEC) and in
other filings the Company makes with the SEC from time to time. In
addition, the forward-looking statements included in this press
release represent the Company’s views only as of the date hereof.
The Company anticipates that subsequent events and developments may
cause the Company’s views to change. However, while the Company may
elect to update these forward-looking statements at some point in
the future, it specifically disclaims any obligation to do so,
except as may be required by law.
For more information, please contact:
Investor Contact:Valter Pinto / Allison
SossKCSA Strategic CommunicationsPhone: 212-896-1254 /
212-896-1267Email: IR@trevena.com
Company Contact:Bob Yoder, SVP and Chief
Business OfficerTrevena, Inc.Phone: 610-354-8840
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Trevena (NASDAQ:TRVN)
Historical Stock Chart
From Sep 2023 to Sep 2024